The Latest Cardiac and Vascular News
COVID-19 Preclinical Work Continues CALGARY, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce today the recent publication of an article titled: “Epigenetic modulation by apabetalone counters cytokine driven acute phase response in […]
CALGARY, Alberta, July 22, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, “We are […]
CALGARY, Alberta, June 22, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix […]
Epigenetic BET-inhibition to combat COVID-19 CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone’s impact on COVID-19 in both a […]
Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure Apabetalone development program moving toward next study to enable a New Drug Application filing CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or […]
CALGARY, Alberta, Feb. 03, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce the U.S. Food & Drug Administration (“FDA”) has granted Breakthrough Therapy Designation for apabetalone in combination with top standard of […]
BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce today additional […]
CALGARY, Alberta, Dec. 20, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company’s Board of Directors. His appointment is effective as of December 19, 2019. […]
CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today. “We would like to thank Eldon for his […]
CALGARY, Alberta, Nov. 25, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company. […]
